| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Naomi Niisato, Yoshinori Marunak. Therapeutic potential of multifunctional myricetin for treatment of type 2 diabetes mellitus. Frontiers in nutrition. vol 10. 2023-06-12. PMID:37305094. |
in this situation, myricetin is being shown to be a multiple bioactive compound to prevent and/or suppress hyperglycemia through inhibiting digestion and uptake of saccharides and enhancing insulin secretion as a possible glp-1 receptor agonist, and to ameliorate t2dm-related complications by protecting endothelial cells from oxidative stress induced by hyperglycemia. |
2023-06-12 |
2023-08-14 |
Not clear |
| Kylie S Chichura, Clinton T Elfers, Therese S Salameh, Varun Kamat, Oleg G Chepurny, Aelish McGivney, Brandon T Milliken, George G Holz, Sarah V Applebey, Matthew R Hayes, Ian R Sweet, Christian L Roth, Robert P Doyl. A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss. Scientific reports. vol 13. issue 1. 2023-06-12. PMID:37308546. |
we demonstrate that two peptide biased agonists (gep44 and gep12) of the glp-1, neuropeptide y1, and neuropeptide y2 receptors (glp-1r, y1-r, and y2-r, respectively) elicit y1-r antagonist-controlled, glp-1r-dependent stimulation of insulin secretion in both rat and human pancreatic islets, thus revealing the counteracting effects of y1-r and glp-1r agonism. |
2023-06-12 |
2023-08-14 |
human |
| Ruben Nogueiras, Michael A Nauck, Matthias H Tschö. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nature metabolism. 2023-06-12. PMID:37308724. |
the glp-1-gip co-agonist tirzepatide was approved in 2022 by the us food and drug administration for the treatment of type 2 diabetes, providing superior hba1c reductions compared to basal insulin or selective glp-1 receptor agonists. |
2023-06-12 |
2023-08-14 |
Not clear |
| Abu Baker Khan, Aimal Shah, Saad Ahmad, Moiz I Khan, Ahsan Ami. Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report. Cureus. vol 15. issue 5. 2023-06-07. PMID:37284401. |
dulaglutide is a synthetic analog of glucagon-like peptide (glp-1) that binds to glp-1 receptors, enhancing insulin secretion and reducing postprandial glucagon and food intake. |
2023-06-07 |
2023-08-14 |
Not clear |
| Tamas T Várkonyi, Anikó Pósa, Noémi Pávó, Imre Pav. Perspectives on weight control in diabetes - Tirzepatide. Diabetes research and clinical practice. 2023-06-06. PMID:37279858. |
besides improvement of glycemic control, tirzepatide treatment is associated with significantly more weight loss as compared to potent selective glp-1 receptor agonists as well as other beneficial changes in cardio-metabolic parameters, such as reduced fat mass, blood pressure, improved insulin sensitivity, lipoprotein concentrations, and circulating metabolic profile in individuals with type 2 diabetes (t2d). |
2023-06-06 |
2023-08-14 |
Not clear |
| Kimberley El, Jonathan D Douros, Francis S Willard, Aaron Novikoff, Ashot Sargsyan, Diego Perez-Tilve, David B Wainscott, Bin Yang, Alex Chen, Donald Wothe, Callum Coupland, Mattias H Tschöp, Brian Finan, David A D'Alessio, Kyle W Sloop, Timo D Müller, Jonathan E Campbel. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature metabolism. 2023-06-05. PMID:37277609. |
the incretins glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance |
2023-06-05 |
2023-08-14 |
human |
| Preetam Guha Ray, Debasis Maity, Jinbo Huang, Henryk Zulewski, Martin Fussenegge. A versatile bioelectronic interface programmed for hormone sensing. Nature communications. vol 14. issue 1. 2023-05-31. PMID:37258547. |
in a proof-of-concept application, we demonstrate that the vibe platform differentiates insulin and glp-1 levels in serum samples of wild-type mice from type-1 and type-2 diabetic mice. |
2023-05-31 |
2023-08-14 |
mouse |
| Tal Davidy, Iscka Yore, Tali Cukierman-Yaffe, Ramit Ravona-Springer, Abigail Livny, Orit H Lesman-Segev, Yossi Azuri, Owen Carmichael, Dimitrios Kapogiannis, Henrik Zetterberg, HungMo Lin, Mary Sano, Michal Schnaider Beer. A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design. Mechanisms of ageing and development. 2023-05-28. PMID:37245533. |
we present the rationale and design of a double-blind placebo-controlled feasibility trial combining intranasal insulin (ini) with dulaglutide, a glp-1 receptor agonist, to improve cognition in older adults with metabolic syndrome (mets) and mild cognitive impairment (mci). |
2023-05-28 |
2023-08-14 |
Not clear |
| Hong-Hong Ma, Jing Zhang, Ci-Qin Li, Li-Wei Zo. Discovery of anthraquinones as DPP-IV inhibitors: Structure-activity relationships and inhibitory mechanism. Fitoterapia. 2023-05-27. PMID:37244503. |
dipeptidyl peptidase iv (dpp-iv) is an integrated type ii transmembrane protein that reduces endogenous insulin contents and increases plasma glucose levels by hydrolyzing glucagon-like peptide-1 (glp-1). |
2023-05-27 |
2023-08-14 |
Not clear |
| Meir Schechter, Cheli Melzer Cohen, Alisa Fishkin, Aliza Rozenberg, Ilan Yanuv, Dvora R Sehtman-Shachar, Gabriel Chodick, Alice Clark, Trine J Abrahamsen, Jack Lawson, Avraham Karasik, Ofri Mosenzo. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovascular diabetology. vol 22. issue 1. 2023-05-27. PMID:37244998. |
kidney function loss and albuminuria progression with glp-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. |
2023-05-27 |
2023-08-14 |
Not clear |
| Yuanzhi Yao, Xiaoying Li, Xiaoqin Yang, Hai Mou, Lin We. Dihydromyricetin promotes GLP-1 release and glucose uptake by STC-1 cells and enhances the effects of metformin upon STC-1 cells and diabetic mouse model. Tissue & cell. vol 82. 2023-05-25. PMID:37229936. |
glucagon-like peptide-1 (glp-1) is an intestinally produced hormone released by the l-cells to stimulate glucose-dependent insulin release. |
2023-05-25 |
2023-08-14 |
mouse |
| Danijel Đekić, Mirjana Bojić, Andrej Janež, Sanja Klobučar, Iris Grčić Hadžimušović, Tijana Ković, Svetla Mihalevsk. Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2023-05-21. PMID:37211579. |
the efficacy of iglarlixi, a fixed-ratio combination of basal insulin glargine 100 units/ml (iglar) and the short-acting glp-1 ra lixisenatide (lixi), was established in people with type 2 diabetes (t2d) who were advancing therapy from oral antidiabetic drugs (oads) and basal insulin (bi). |
2023-05-21 |
2023-08-14 |
Not clear |
| Matthias Tschöp, Ruben Nogueiras, Bo Ahré. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia. 2023-05-20. PMID:37209227. |
they mimic the action of glp-1 to reduce glucose levels through stimulation of insulin secretion and inhibition of glucagon secretion. |
2023-05-20 |
2023-08-14 |
Not clear |
| Sundararajan Mahalingam, Ramesh Bellamkonda, Madan Kumar Arumugam, Sathish Kumar Perumal, Jessica Yoon, Carol Casey, Kusum Kharbanda, Karuna Rasinen. Glucagon-like peptide 1 receptor agonist, exendin-4, reduces alcohol-associated fatty liver disease. Biochemical pharmacology. 2023-05-20. PMID:37209859. |
of current interest to our laboratory is glucagon-like peptide 1 (glp-1), a widely studied hormone known to reduce insulin resistance and hepatic fat accumulation in patients with metabolic-associated fatty liver disease. |
2023-05-20 |
2023-08-14 |
rat |
| Gaber El-Saber Batiha, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Nada A Ashour, Walaa A Neg. Potential role of tirzepatide towards Covid-19 infection in diabetic patients: a perspective approach. Inflammopharmacology. 2023-05-19. PMID:37208555. |
the beneficial effect of tzt in t2dm and obesity is related to direct activation of gip and glp-1 receptors with subsequent improvement of insulin sensitivity and reduction of body weight. |
2023-05-19 |
2023-08-14 |
Not clear |
| Hernando Vargas-Uricoechea, Juan Pablo Frias, Hernando David Vargas-Sierr. Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials. The review of diabetic studies : RDS. vol 19. issue 1. 2023-05-16. PMID:37185053. |
the purpose of this review was to evaluate and analyze the results of pivotal studies with both fixed-ratio combinations in individuals with type 2 diabetes, finding that, they are capable of achieving better glycemic control when compared with each of its components separately (with a lower risk of hypoglycemia vs basal insulin and lower risk of gastrointestinal adverse effects vs glp-1 receptor agonists) in various clinical scenarios, especially in individuals who do not achieve control with oral antidiabetics or who do not achieve control with basal insulin (associated with oral antidiabetics) or in those under management with glp-1ra plus oral antidiabetics. |
2023-05-16 |
2023-08-14 |
Not clear |
| Magdalena Wronka, Julia Krzemińska, Ewelina Młynarska, Jacek Rysz, Beata Franczy. New Insights into the Use of Liraglutide-Impact on Cardiovascular Risk and Microvascular Outcomes. Biomedicines. vol 11. issue 4. 2023-05-16. PMID:37189777. |
one of them is liraglutide, which belongs to long-acting analogs of glucagon-like peptides-1 (glp-1); it imitates incretins and causes an increase in insulin secretion. |
2023-05-16 |
2023-08-14 |
Not clear |
| Mireia Montaner, Jessica Denom, Wanqing Jiang, Christophe Magnan, Stefan Trapp, Hirac Gurde. The local GLP-1 system in the olfactory bulb is required for odor-evoked cephalic phase of insulin release in mice. Molecular metabolism. 2023-05-14. PMID:37182561. |
the local glp-1 system in the olfactory bulb is required for odor-evoked cephalic phase of insulin release in mice. |
2023-05-14 |
2023-08-14 |
mouse |
| Damien Denimal, Victoria Bergas, Jean-Paul Pais-de-Barros, Isabelle Simoneau, Laurent Demizieux, Patricia Passilly-Degrace, Benjamin Bouillet, Jean-Michel Petit, Alexia Rouland, Amandine Bataille, Laurence Duvillard, Bruno Vergè. Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes. Cardiovascular diabetology. vol 22. issue 1. 2023-05-04. PMID:37143040. |
on the other hand, the glp-1 receptor agonist liraglutide reduces major adverse cardiac events, insulin resistance and liver steatosis in t2d patients. |
2023-05-04 |
2023-08-14 |
Not clear |
| Prawej Ansari, Sara S Islam, Samia Akther, Joyeeta T Khan, Jaber A Shihab, Yasser H A Abdel-Waha. Insulin secretory actions of ethanolic extract of Acacia arabica bark in high fat-fed-diet induced obese type 2 diabetic rats. Bioscience reports. 2023-05-03. PMID:37133312. |
similarly, eeaa at 10-40 µg/ml demonstrated a substantial (p<0.05-0.001) insulin secretory effect with 16.7 mm glucose from isolated mouse islets, with a magnitude comparable to 1 µm glp-1. |
2023-05-03 |
2023-08-14 |
mouse |